Affymax to Participate on Panel at RBC Capital Markets Healthcare Conference

Business Wire, Dec 6, 2007

PALO ALTO, Calif. -- Affymax, Inc. (Nasdaq:AFFY) today announced that Paul Cleveland, the company's executive vice president and chief financial officer, will participate on the Replacing the Mainstay with Newer and Better Agents panel at the RBC Capital Markets Healthcare Conference on Wednesday, December 12, 2007, at 4:30 p.m. ET at the Westin New York at Times Square.

A live audio webcast of the panel discussion will be available on the investors section of the company's website at www.affymax.com. A replay will also be available for 30 days following the presentation.

About Affymax, Inc.

Affymax, Inc. is a biopharmaceutical company developing novel drugs to improve the treatment of serious and often life-threatening conditions. Affymax's lead product candidate, Hematide[TM], is currently in Phase 3 clinical trial stage for the treatment of anemia associated with chronic renal failure and in clinical trials for the treatment of anemia in cancer patients. For additional information, please visit www.affymax.com.